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Treatment of high-risk patients is a major challenge in multiple myeloma. This is especially true for 
patients assigned to the gene-expression-profiling defined proliferation subgroup. Although recent 
efforts have identified some key players of proliferative myeloma, genetic interactions and players 
that can be targeted with clinically effective drugs have to be identified to overcome the poor 
prognosis of these patients. We therefore examined maternal embryonic leucine zipper kinase 
(MELK) for its implications in hyper-proliferative myeloma and analysed the activity of the MELK 
inhibitor OTSSP167 in vitro and in vivo. MELK was found to be significantly overexpressed in the 
proliferative subgroup of myeloma. This finding translated into poor overall survival in patients with 
high vs. low MELK expression. Enrichment analysis of upregulated genes in myeloma cells of MELK
high 
patients confirmed the strong implications in myeloma cell proliferation. Targeting of MELK with 
OTSSP167 impaired the growth and survival of myeloma cells, thereby affecting central survival 
factors such as MCL-1 and IRF4. This activity was also observed in the 5TGM.1 murine model of 
myeloma. OTSSP167 reduced bone marrow infiltration and serum paraprotein levels in a dose-
dependent manner. In addition, we revealed a strong link between MELK and other proliferation 
associated high-risk genes (PLK-1, EZH2, FOXM1, DEPDC1) and MELK inhibition also impaired the 
expression of those genes. We therefore conclude that MELK is an essential component of a 
proliferative gene signature and that pharmacological inhibition of MELK represents an attractive 






The implementation of novel treatment opportunities continuously improved the outcome of 
multiple myeloma (MM) patients throughout the last decades. 
1
 However, clinical progress is mainly 
based on superior outcome in standard risk patients, while the outcome in high-risk patients is still 
limited. 
2,3
 Deciphering gene networks and drug candidates in high-risk MM remains a major task to 
improve the prognosis of all MM patient subgroups. 
Common classifications use tumour load and the presence of fluorescence-in-situ-hybridization 
(FISH) determined cytogenetic aberrations to define high-risk patients. 
4
 More sophisticated methods 
include flow cytometry and gene expression profiling (GEP) to characterize patients with poor 
prognosis. 
5–10
 The latter enabled the classification of MM into distinct GEP-defined subgroups. 
10
 
These subgroups are typically linked to the cytogenetic profile of MM (presence of distinct IgH 
translocations or hyperdiploidy). However, GEP studies also elucidated a proliferation associated 
subtype. 
10
 GEP-defined myeloma with a proliferative character is strongly associated with high-risk 
scores and, consequently, poor prognosis. 
8–10
 Importantly, outcome of this patient subgroup remains 
poor with current treatment strategies and therefore requires the implementation of more 
specialized treatment approaches to improve survival rates. 
Recent efforts have identified several key proliferative genes in MM. Among others, aurora kinase A 
(AURKA), 
11
 polokinase-1 (PLK1), 
12,13
 pituitary tumour transforming gene 1 (PTTG1) 
14
 and DEPDC1A 
15
 
overexpression has been reported in proliferative MM and linked to poor prognosis. Targeting of 
these genes impaired the growth and survival of MM cells, but their functional relevance for the 
proliferative character in MM is unclear. Moreover, information about interactions or the hierarchy 
of individual candidate genes is limited at the moment. In this context, FOXM1 was recently reported 
to be a putative driver in high-risk MM. 
16
 A tight relationship between FOXM1, CDK6 and NEK2 
suggested a functional role for this transcription factor in promoting high-risk disease. CDK6 and 
NEK2 are transcriptional targets of FOXM1 and co-regulation of FOXM1 with these genes was linked 
to poor outcome. In addition, physical interaction between CDK6 and FOXM1 was suggested to 
further promote FOXM1-mediated gene transcription. 
16
 However, central drivers of proliferation 
associated high-risk MM remain undisclosed and clinical grade inhibitors for many recently 
characterized target genes (e.g. FOXM1) are missing.  
Maternal embryonic leucine zipper kinase (MELK), a serine/threonine kinase with strong implications 
in cell cycle progression, 
17,18
 was identified as an upstream regulator of FOXM1 in solid and 
haematological malignancies. 
19,20
 MELK plays a functional role during cell cycle progression via a 





Overexpression of MELK as well as an association between MELK levels and poor prognosis has been 
reported in various malignancies. 
21–26
 MELK was shown to play a role in the proliferation and survival 
of malignant cells and to support the growth of cancer stem cells. 
27–29
 Mechanistically, MELK was 
found to regulate FOXM1 mediated expression of mitotic genes in a PLK1 dependent manner in 
glioblastoma and to induce EZH2 expression in irradiation-resistant glioma stem cells. 
19,30
 More 
recent studies revealed additional MELK targets (e.g. DEPDC1) and demonstrated disruption of the 
MELK associated gene network by using the MELK inhibitor OTSSP167 in solid and haematological 
malignancies. 
20,31,32
 These reports placed MELK upstream of several genes independently linked to 
high-risk myeloma, including FOXM1, EZH2, PLK1 and DEPDC1. 
12,13,15,16,33
 Considering the availability 
of a MELK small molecule inhibitor (OTSSP167) already undergoing clinical testing 
34
, we therefore 




See the Online Supplementary Materials and Methods for a description of the techniques. 
Cells  
Human multiple myeloma cell lines (HMCLs) U266, KMS-12-BM, OPM-2, NCI-H929, SK-MM-1 and 
RPMI8226, MM.1S, and MM.1R as well as immortalized bone marrow mesenchymal stromal cells 
(kindly provided by Dr. Dario Campana, St. Jude Children's Research Hospital, Memphis, TN) were 
cultivated as previously described. 
35
 5TGM.1GFP+ cells (kind gift of Dr. G. Mundy, Vanderbilt 
University, Nashville, TN, USA) and HEK293T cells were maintained in DMEM, supplemented with 
10% FBS, 2 mM L-glutamine and 1% penicillin/streptomycin.  
Cytotoxicity and colony formation assays 
Cytotoxicity and colony formation assays were performed using Cell Counting Kit 8 (Sigma-Aldrich) 





All assays were performed according to the manufacturer’s instructions as described previously. 
35
 
Analyses were performed on a FACScan and FACS Canto II (BD Biosciences). 
In vivo study 
For studies in the murine 5TGM.1 myeloma model, OTSSP167 was dissolved in 0.5% methylcellulose 
(Sigma-Aldrich) and administered by oral gavage at different dose levels. For every experimental 
cohort, mice were randomly divided in a naïve group (n=5, healthy controls), a vehicle group (n=10, 
myeloma-bearing mice receiving vehicle solution) and a treated group (n=10, myeloma-bearing mice 
receiving OTSSP167). These experiments were performed as previously described. 
36
 Institutional 
Animal Care and Use Committee (ICACUC) approval number is 1336. The accreditation number 
from the Belgian government is LA16100002/LA2610359. 
 
Statistical analysis 
Patients groups exhibiting higher or lower target gene expression were defined with the maximally 
selected rank statistics, implemented in the maxstat R package. Statistical significance of differences 
in overall survival was calculated by the log-rank test, and survival curves were plotted using the 
Kaplan-Meier method. Pearson correlations were calculated using R´s cor.test function. For the 
analysis of in vitro and in vivo experiments, two-tailed unpaired t test was performed for comparison 
6 
 
of 2 means and one-way ANOVA followed by a Tukey’s post-hoc test for comparison of multiple 
means by Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). P values <0.05 were considered to be 
statistically significant. Drug combinations were analysed with CompuSyn software. Combination 
index (CI) values <0.85, 0.85-1.15, and >1.15 were interpreted as synergistic, additive, and 
antagonistic drug activity, respectively. All graphs represent the meanV±standard deviation of at 





MELK expression is elevated in proliferation associated high-risk myeloma and linked to poor 
outcome 
To study the clinical relevance of MELK in MM, we analysed MELK gene expression levels in publically 
available GEP datasets. No significant difference was observed between gene expression levels of 
healthy donor bone marrow plasma cells (BMPCs), monoclonal gammopathy of undetermined 
significance (MGUS) and smouldering multiple myeloma (SMM) patient cells but we noted a stepwise 
increase from MGUS/SMM cells to newly diagnosed and relapsed myeloma (Figure 1A). Analysis of 
MELK expression in distinct GEP-defined subgroups (according to Zhan et al. 
10
) revealed significant 
overexpression of MELK in newly-diagnosed patients categorized into the proliferation (PR) subgroup 
of MM (Figure 1B). Consequently, high MELK expression levels were associated with poor outcome in 
patients treated within the total therapy 2 (median OS not reached vs. 81.47 months, P=0.01), total 
therapy 3 (median OS not reached, P<0.0001) as well as bortezomib and/or dexamethasone based 
protocols (median OS 21.1 months vs 11.2 months, P=0.02) (Figure 1C). A similar association was 
noted with PANP defined detectable and absent MELK expression as cut-off (Supplementary Figure 
1). Moreover, comparison of MELK expression levels in MM patients at baseline vs. relapse indicated 
significant MELK upregulation in CD138-purified BM cells of relapsed patients, suggesting selection of 
MELK
high 
MM cells or increasing MELK expression upon treatment which could be implicated in drug 
resistance (Figure 1D). To further strengthen the link between MELK and high-risk disease we 
analysed MELK expression levels using independent GEP-datasets which contained samples from 
patients with plasma cell leukaemia (PCL). This clearly demonstrated upregulation of MELK in PCL 
compared to MM, therefore underlining the strong association between MELK expression and 
aggressive disease (Figure 1 E-F).  
 
MELK expression is strongly associated with cell cycle regulation 
In order to confirm the association of MELK with proliferation in MM, we analysed GEP data 
(GSE24080) of newly-diagnosed MM patients (n=551) with high vs. low levels of MELK. This depicted 
266 upregulated and 5 downregulated probe sets representing 235 genes (minimum fold change >2) 
in patients with high compared to low MELK expression (Supplementary Table 1). High MELK 
expression levels were associated with elevated transcription of several genes implicated in cell cycle 
regulation such as CDK1, CCNB1, CCNB2, AURKA, KIF11, or BUB1B. This was confirmed by Metacore 
enrichment analysis. The top10 GO processes, pathway maps and process networks demonstrated a 
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significant enrichment for cellular processes involved in cell cycle regulation (Supplementary Table 
2). In sum, these results demonstrate a significant association of MELK with proliferation associated 
high-risk myeloma and therefore encouraged pre-clinical testing of MELK as novel therapeutic target 
in MM. 
 
Targeting of MELK impairs the growth and survival of myeloma cells 
In line with their proliferative character 
9
, MELK mRNA and protein expression was detected in all 
HMCLs analysed (Figure 2A). Targeting of MELK via shRNA significantly impaired the growth of KMS-
12-BM and MM.1S cells (Figure 2B). We therefore continued to study the impact of MELK inhibition 
on MM cells using a small molecule inhibitor of MELK (OTSSP167). Treatment with OTSSP167 leads to 
destabilization of MELK and subsequent loss of MELK protein levels. 
31
 Accordingly, OTSSP167 
downregulated MELK protein levels 24h post treatment and reduced the viability of all tested HMCLs 
(median IC50: 10.2 nM, range: 7.6 – 27.1 nM) (Figure 2 C-D). Moreover, OTSSP167 showed similar 
activity in 6 of 7 primary MM cell samples obtained from patients with heavily pre-treated disease 
(Figure 2E, see Supplementary Table 3 for patient characteristics). Due to the short-lived viability of 
in vitro propagated primary MM cells we also analysed the activity of OTSSP167 in co-culture with 
bone marrow stromal cells (BMSCs). In line with the reported supportive role of BMSCs this 
demonstrated a pro-survival effect on the viability of primary MM cells. Importantly, OTSSP167 
completely abrogated the protective effect of BMSCs and eradicated viable MM cells obtained from 
patients with plasma cell leukemia or refractory MM (Figure 2F). In contrast, OTSSP167 displayed 
only a minor impact on the viability of human PBMCs or BMSCs at effective anti-MM concentrations 
(median IC50: 726 nM) (Supplementary Figure 3). 
Inhibition of MELK was accompanied by a rapid downregulation of central myeloma genes. In line 
with the proposed involvement of MELK in the G2/M phase of the cell cycle we observed reduced 
gene expression levels of CCNB1, AURKA and PLK1 5h post treatment with OTSSP167 (Figure 3A). A 
significant correlation of MELK expression levels and those of CCNB1 (R=0.82, P<0.00001), AURKA 
(R=0.70, P<0.00001) and PLK1 (R=0.38, P<0.00001) was noted in publically available GEP data 
(GSE24080) (not shown). In addition, we also observed decreased expression of the prominent 
myeloma survival factors MCL-1 and IRF4 (Figure 3A). These findings translated into a significant 
accumulation of cells in the G2/M phase of the cell cycle as well as induction of apoptosis 48 hours 
and 72 hours post treatment, respectively (Figure 3 B-C). The latter was verified by a significant 
increase of AnnexinV/7-AAD positive cells (Figure 3C) and associated with a loss of the mitochondrial 
membrane potential, detection of cleaved PARP and cleaved caspase3 (Figure 3 D-F). Moreover, 
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decreased expression of IRF4 and MCL-1 translated into reduced protein levels 24h post treatment 
(Figure 3F).  
Importantly, the anti-myeloma activity of OTSSP167 was upheld in the presence of BMSCs. Similar 
frequencies of apoptotic cells were observed in co-cultures compared to mono-cultures 
(Figure 3 C, G). We also observed reduced clonogenic growth in OTSSP167 treated HMCLs 
(Figure 3H). This suggests an impact of MELK inhibition on tumour propagating cells as well.  
 
OTSSP167 displays strong synergism with immunomodulatory drugs and dexamethasone 
To examine a potential impact of OTSSP167 on the activity of established anti-myeloma drugs, we 
performed drug combination studies with IMiDs (lenalidomide, pomalidomide), proteasome 
inhibitors (bortezomib, carfilzomib), dexamethasone, melphalan and bendamustine. These 
experiments demonstrated synergistic activity (CI<0.85) of OTSSP167 with IMiDs and 
dexamethasone, while combination studies with proteasome inhibitors displayed varying results. In 
detail, combination of OTSSP167 with IMiDs displayed synergistic or additive drug activity in 22 of 24 
combinations tested. Median combination index (CI) values for lenalidomide and pomalidomide were 
0.76 (range: 0.49-1.29) and 0.48 (range: 0.12-1.12), respectively. Strong synergistic activity of 
OTSSP167 was also observed in combination with dexamethasone. 11 of 12 combinations were 
synergistic (1 additive) with CI values ranging from 0.20-1.12 (median 0.43) (Figure 4A). In contrast, 
13/21 evaluable combinations with PIs displayed antagonistic drug activity. Mainly additive effects 
were observed when OTSSP167 was combined with the alkylating drugs melphalan (median CI: 0.86, 
range: 0.34-1.27) and bendamustine (1.03, 0.63-1.62) (Supplementary Figure 4). 
We further confirmed the strong synergism between OTSSP167 and IMiDs as well as dexamethasone 
using a wider range of drug concentrations. This corroborated our results as OTSSP167 showed 
consistent synergism with IMiDs and dexamethasone independent of the concentrations used 
(Supplementary Table 4). Finally, we examined whether OTSSP167 is synergistic in combination with 
lenalidomide/pomalidomide plus dexamethasone. OTSSP167 displayed strong synergism with this 
well-established treatment regimen (median CI of OTSSP167 with Len-Dex: 0.15, range: 0.02-0.46; 
Pom-Dex: 0.09, range: 0.003-0.28). In spite of the potent combinatorial effect of IMiDs-
dexamethasone, OTSSP167 further improved the efficacy of this combination; in particular in OPM-2 





OTSSP167 impairs myeloma cell growth in vivo 
Treatment of murine 5TGM.1 MM cells with OTSSP167 demonstrated anti-myeloma activity similar 
to the effects observed in HMCLs. MELK transcript levels were in the range of HMCLs (not shown) 
and we observed a dose-dependent reduction of MELK protein levels and viability 24h and 96h post 
treatment, respectively. Moreover, OTSSP167 induced G2/M phase cell cycle arrest and apoptosis in 
5TGM.1 cells (Figure 5A). This impact translated to the in vivo setting. OTSSP167 strongly reduced 
tumour burden in the 5TGM.1 murine model of myeloma. This was evidenced by several indicators 
including BM plasma cell infiltration, spleen weight and serum IgG2b levels (Figure 5 C-E). We 
observed a dose-dependent reduction of myeloma growth in the BM and spleen weight as well as 
normalization of paraprotein levels. In addition, OTSSP167 significantly enhanced the well-being of 
myeloma-bearing mice indicated by absence of paraplegia and increased activity (Figure 5F).  
 
Inhibition of MELK impairs a proliferation associated myeloma high-risk gene signature 
We next sought to decipher the relationship of MELK with other genes associated with high-risk 
disease. Similar to MELK, PLK1 is significantly upregulated in the GEP-defined PR subgroup of MM. 
12
 
Other genes associated with poor outcome in MM and/or known functional ties with MELK include 
FOXM1, EZH2, and DEPDC1. 
15,16,37
 Strikingly, all of these genes are significantly upregulated in the PR 
subgroup and associated with poor outcome. Correlation analysis confirmed a strong association 
between MELK expression levels and those of the other high-risk genes in MM cells (Figure 6A, 
Supplementary Figure 2). We therefore tested the impact of MELK inhibition on the expression of 
those genes. Treatment with OTSSP167 (24h) led to a significant downregulation of PLK1 and EZH2 
transcript levels (Figure 6B). Moreover, OTSSP167 downregulated PLK1, FOXM1, EZH2 and DEPDC1 
protein levels in concert with MELK suggesting a functional relationship of these genes in MM. This 
observation was confirmed with shRNA mediated MELK knockdown (Figure 6 C-D).  
To better understand the genetic network of these molecules and to reveal additional network 
partners, we analysed the interactions of the five high-risk genes using GeneMANIA. This 
demonstrated close interactions of all five candidate genes in concert with several cell cycle 
associated genes (Figure 6E). The top 6 annotated functions of this network were all linked to cell 
cycle regulation (cell cycle G2/M-phase transition, G2/M-phase transition of mitotic cell cycle, 
condensed chromosome kinetochore, nuclear division, condensed chromosome centromeric region, 
mitosis; false discovery rate <1.10x10
-9
). Importantly, 9 of 20 proposed network genes (CENPA, PRC1, 
CCNB1, CCNB2, MKI67, TOP2A, CDK1, NEK2, GTSE1) were also found to be elevated in newly-
diagnosed MM patients with high MELK expression (Supplementary Table 1) and nine genes of the 
11 
 
proposed network plus input genes are among the top 50 overexpressed genes of the GEP-defined 
PR subgroup (DEPDC1, EZH2, FOXM1, NEK2, CCNB1, TOP2A, PRC1, CCNB2, and BIRC5) (Figure 6E). 
The clinical relevance of this gene network was evident in patients treated within the total therapy 2 
and 3 trials. Patients with elevated expression of 3 or more high-risk genes (MELK, PLK1, EZH2, 
FOXM1, DEPDC1) displayed a significantly shorter OS compared to patients with low expression 
levels of these genes or only 1-2 genes with high expression (median OS 37.1 months vs not reached, 
P<0.0001; Figure6F). In sum, these data strengthen our prior results and suggest a direct impact of 





The characterization of novel treatment opportunities for high-risk patients is a major task in current 
myeloma research. Here, we identified MELK as putative anti-MM target in the proliferation 
associated high-risk subgroup of MM and underlined its role as attractive drug target in vitro and in 
vivo. MELK was significantly overexpressed in MM patients of the GEP-defined proliferation subgroup 
and associated with several genes implicated in cell cycle progression, especially at the G2/M phase. 
Interestingly, we also observed overexpression of MELK at relapse and in plasma cell leukaemia 
pointing to the reported acquisition of a proliferative character post anti-myeloma therapy. 
10
 This 
finding underlines the association between MELK and aggressive disease. Moreover, upregulation of 
MELK or selection of MELK
high 
MM cells during the course of the disease suggests that a broad patient 
population could benefit from OTSSP167 treatment compared to a relatively small fraction of 
patients at baseline (approximately 15% of patients are categorized into the PR subgroup at 
diagnosis 
38
). These initial data therefore strongly supported pre-clinical testing of MELK as novel 
drug target for high-risk MM. 
Targeting of MELK with specific shRNA significantly reduced the growth of HMCLs. We therefore 
studied the impact of pharmacological inhibition of MELK using OTSSP167, currently under 
investigation in several preclinical and clinical studies. OTSSP167 impairs the auto-phosphorylation of 
MELK leading to subsequent degradation and loss of endogenous MELK protein. 
31,39
 Accordingly, we 
observed a dose dependent decrease of MELK protein levels 24h post treatment and significant anti-
MM activity in vitro. This is in line with a recent report demonstrating potent anti-myeloma activity 
of OTSSP167 in a panel of MM cell lines in vitro. 
32
 Our findings corroborate the impact of OTSSP167 
on the viability of myeloma cells in mono- and co-culture, demonstrate potent activity in primary 
MM cells from high-risk patients and also validated the impact of OTSSP167 on tumour propagating 
cells using an independent (colony formation) assay. We also demonstrated that the induction of 
apoptosis coincides with the depolarization of the mitochondrial membrane and loss of Mcl-1, a key 
anti-apoptotic protein in HMCLs. 
40
 This fits well to recent findings demonstrating Mcl-1 protein 
synthesis in a MELK dependent manner. 
41
 Rapid loss of MCL-1 might also explain the adverse effects 
of combining OTSSP167 with proteasome inhibitors. 
42
 In contrast, treatment with OTSSP167 in 
combination with IMiDs and dexamethasone demonstrated strong synergistic activity and therefore 
proved the applicability and benefit of this drug in combination with established anti-MM agents. 
The strong synergism observed with Len- or Pom-Dex suggests that OTSSP167 might even enhance 
the activity of this backbone regimen. OTSSP167 was shown to specifically target MELK in different 
pre-clinical in vivo models without the induction of severe events. 
25,31,34,
 Two phase I studies 
assessing the safety and bioavailability of OTSSP167 have been recently completed (results not 
13 
 
published); two additional studies in breast cancer and haematological malignancies are currently 
ongoing. In the case of no severe toxicities OTSSP167 should be strongly considered for clinical 
testing in MM, especially due to its availability as oral agent and its positive impact on the activity of 
established myeloma-drugs.  
Importantly, the anti-myeloma activity of OTSSP167 was confirmed in vivo. We observed a dose-
dependent reduction of tumour growth in the murine 5TGM.1 MM-model. Moreover, treatment 
displayed a significant increase in the well-being of mice even at sub-optimal anti-myeloma activity. 
The potent in vivo activity of OTSSP167 confirmed the role of MELK as novel target in the presence of 
stromal support and suggests that OTSSP167 inhibits tumour initiating cells in vivo. Effective 
targeting of myeloma stem cells was reported by blocking the MELK associated factor EZH2. 
33
 Hence, 
MELK inhibition might exert its anti-myeloma activity via affecting key players of MM 
pathophysiology linked to tumour propagation and high-risk disease. 
Recent work in glioblastoma revealed a central role for MELK in the regulation of FOXM1 mediated 
cellular proliferation in a PLK1 dependent manner and EZH2 mediated irradiation resistance. 
19,30
 In 
addition, OTSSP167 was recently shown to target DEPDC1. 
31
 These genes were previously described 
as therapy targets in MM and reported to be associated with high proliferation and/or poor 
survival. 
12,13,15,16,37
 We demonstrated a significant correlation of MELK with all four candidate genes 
and confirmed the negative impact of these genes on the outcome of myeloma patients. 
Noteworthy, overexpression of at least 3 of 5 proliferation associated high-risk genes was required to 
unfold their poor prognostic role. This is a key finding of the current study as it clearly demonstrates 
that not a single gene, but rather networks of closely interconnected genes drive aggressive disease. 
Importantly, targeting of MELK affected the protein synthesis of all other high-risk genes. Of note, 
OTSSP167 reduced the gene expression levels of PLK1 and EZH2 but not those of DEPDC1 and 
FOXM1. In line with this observation, a recent study demonstrated that MELK stabilizes DEPDC1 at 
the protein level via phosphorylation without affecting DEPDC1 transcription. 
31
 Stable expression of 
FOXM1 at the mRNA level despite modulation of MELK is also in line with a previous report. 
19
 
Moreover, two additional studies demonstrated a decrease of FOXM1 protein expression post 
OTSSP167 treatment but did not provide data about FOXM1 mRNA levels. 
20,32
 Given that MELK 
stimulates FOXM1 activation in a PLK1 dependent manner we hypothesize two pathways that lead to 
the observed loss of FOXM1 protein expression. First, rapid downregulation of PLK1 (evident 6h post 
treatment) likely results in reduced FOXM1 activation. Second, FOXM1 is required for mitotic 
progression and a loss of activity likely contributes to the observed arrest of MM cells at the G2/M 
stage of the cell cycle as well as reduced expression of MELK-FOXM1 downstream target genes such 
as EZH2. 
30,43
 As FOXM1 undergoes proteasomal degradation upon mitotic arrest, a process 
14 
 
accelerated by FOXM1 sumoylation, 
43
 we believe that this explains the observed discrepancy 
between mRNA and protein levels. However, based on recent findings we cannot exclude potential 
MELK-independent (off-target) effects of OTSSP167 on these cell cycle associated genes 
44
 and 
therefore, further research efforts are required to reveal the exact sequence of OTSSP167 mediated 
anti-tumour mechanisms and the hierarchy of the MELK associated gene network. 
In silico analysis placed MELK in a network with strong enrichment for key genes of the GEP-defined 
proliferation subgroup (DEPDC1, EZH2, FOXM1, NEK2, CCNB1, TOP2A, PRC1, CCNB2, and BIRC5). This 
suggests that MELK is an important orchestrator of a whole set of proliferative network genes and 
blocking of MELK seems to represent a promising future strategy to target proliferation associated 
myeloma. Independent confirmation of this assumption was obtained from a recent in silico analysis 
of 645 patients treated within the CoMMpass trial. This study revealed MELK as top driver of a cell 
cycle associated pathway in high-risk MM. 
45
 Although further studies have to decipher the exact 
interaction network and hierarchy of MELK with other high-risk genes, our study highlights the strong 
relation of MELK with proliferation associated genes and its role as a potential drug target for this 
group of patients. 
Taken together, our data reveal MELK as a novel prognostic marker of proliferation associated high-
risk myeloma and attractive drug target in MM. Targeting of MELK demonstrated potent anti-
myeloma activity, enhanced the activity of IMiDs and dexamethasone, and impaired tumour 
propagating cells. Furthermore, we demonstrated a strong relationship between MELK and 
proliferation as well as other proliferation associated high-risk genes. This suggests that MELK, in 
conjunction with other high-risk genes, plays an essential role in the regulation of the proliferative 
phenotype of MM and that selective targeting of MELK could impair a whole network of central 
drivers of proliferation associated MM. These results therefore warrant further investigation about 
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Figure 1 │ MELK is overexpressed in proliferation associated myeloma and linked to poor outcome. 
A) Analysis of publically available gene expression (GEP) data demonstrated significant 
overexpression of MELK in CD138
+
 purified cells of MM patients compared to MGUS and SMM 
patients as well as healthy donor bone marrow plasma cells (BMPCs). B) Analysis of MELK expression 
in distinct GEP-defined subgroups revealed significant overexpression in the proliferation (PR) 
associated subgroup of MM. CD1, CCND1 group; CD2, CCND3 group; HY, hyperdiploid group; LB, low 
bone disease group; MF, Maf/MafB group; MS, MMSET group; MY, myeloid signature group. C) High 
MELK expression was associated with poor outcome in newly-diagnosed patients treated within the 
total therapy 2 and 3 protocols (GSE24080) as well as relapsed and/or refractory patients (GSE9782) 
treated with bortezomib or dexamethasone. D) MELK expression was elevated at relapse compared 
to baseline in patients treated within the TT2 (n=127 and n=343, respectively) and TT3 (n=29 and 
n=453, respectively) protocols as well as other treatment strategies (n=98). E-F) MELK expression was 
significantly elevated in CD138
+
 purified cells of patients suffering from plasma cell leukemia 
compared to BMPC, MGUS and MM cell samples. Horizontal lines indicate geometric mean with 95% 
confidence interval. * P<0.05, ** P<0.01, ***P<0.001. 
 
Figure 2 │ Targeting of MELK impairs myeloma cell growth. A) MELK protein and mRNA expression 
in human myeloma cell lines (HMCLs). B) KMS-12-BM and MM.1S cells transduced with MELK specific 
shRNA show significantly impaired cell growth compared to cells transduced with control vector 
carrying scrambled shRNA. **P<0.01 C) Treatment with OTSSP167 reduces MELK protein expression 
in HMCLs in a dose dependent manner. Viability of (D) HMCLs and (E) primary MM cells 96 h post 
treatment with OTSSP167. (F) Viable primary MM cells were assessed by Annexin V / 7-AAD staining 
72h post treatment with OTSSP167 in the presence (co-culture) or absence (mono-culture) of bone 
marrow stromal cells (BSMCs).  
 
Figure 3 │ OTSSP167 impairs the cell cycle at the G2/M phase and induces apoptosis in MM cells. 
A) Transcript levels of MM related growth and survival genes 5 h post treatment with OTSSP167 at 
the indicated concentrations. Gene expression levels are displayed relative to the control (0.1% 
DMSO). B) Cell cycle distribution of HMCLs 48 h post treatment with either 0.1% DMSO (control) or 
OTSSP167. C-E) Induction of apoptosis was verified by (C) Annexin V / 7-AAD staining, (D) loss of the 
mitochondrial membrane potential, and (E) increased levels of cleaved PARP. F) Representative 
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Western Blot images of HMCLs 24 h post treatment with either 0.1% DMSO (control) or OTSSP167. G) 
OTSSP167 induces apoptosis in MM cells in the presence of bone marrow stromal cells. H) OTSSP167 
inhibited colony formation of HMCLs. Images are representative for three independent experiments. 
*P<0.05, **P<0.01, ***P<0.001 compared to control. 
 
Figure 4 │ OTSSP167 displays synergistic activity with IMiDs and dexamethasone. (A) HMCLs were 
treated with OTSSP167 in combination with immunomodulatory drugs (lenalidomide, pomalidomide) 
or dexamethasone for 96 h at the indicated concentrations. Combination index (CI) values were 
determined with Compusyn. CI values <0.85, 0.85-1.15, or >1.15 indicate synergistic (*), additive (+) 
or antagonistic (#) drug activity, respectively. (B) The activity of OTSSP167 in combination with 
dexamethasone PLUS lenalidomide or pomalidomide is compared to the corresponding monodrugs 
and dual-combinations. All data points of the triple combination in all three cell lines displayed strong 
synergism (CIs< 0.5 and 0.3 for lenalidomide and pomalidomide containing treatments, respectively; 
not indicated in the graph). 
 
Figure 5 │ OTSSP167 impairs myeloma cell growth in vivo. A) In vitro evaluation of OTSSP167 in 
murine 5TGM.1 myeloma cells reduced MELK protein levels and cell viability in a dose dependent 
manner 24h and 72h post treatment, respectively. This was accompanied by a significant increase of 
cells in the G2/M phase of the cell cycle 24h after treatment initiation and accumulation of apoptotic 
cells 72h post treatment. B) OTSSP167 treatment schedule in the 5TGM.1 murine model of myeloma. 
Treatment of myeloma bearing mice with OTSSP167 led to a dose-dependent reduction of (C) bone 
marrow plasma cell infiltration rate, (D) spleen weight and (E) serum IgG2b levels. In addition, the 
paraplegia score (based on presence and severity of paraplegia, altered posture and diminished 
activity) of OTSSP167 treated mice significantly improved compared to vehicle treated mice (F). 
Boxplots represent median (horizontal line) with min-max whiskers. **P<0.01, ***P<0.001 compared 
to vehicle treated control mice. 
 
Figure 6 │ MELK is an essential component of a proliferation associated high-risk network. A) Gene 
expression levels of PLK1, EZH2, FOXM1 and DEPDC1 are significantly elevated in the proliferation 
(PR) associated subgroup of myeloma (*P<0.05, **P<0.01, ***P<0.001 compared to all other 
subgroups) and show a significant correlation with MELK expression levels. Horizontal lines indicate 
geometric mean with 95% confidence interval. B) Gene expression levels of PLK1, EZH2, FOXM1 and 
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DEPDC1 in HMCLs 24 h post treatment with OTSSP167. *P<0.05, **P<0.01, ***P<0.001 compared to 
control cells (0.1% DMSO). C, D) Protein expression of PR associated high-risk genes (C) 24 h post 
treatment with OTSSP167 or (D) in cells transduced with a MELK specific shRNA. E) The five genes 
MELK, PLK1, EZH2, FOXM1 and DEPDC1 (marked in red) were used to reveal an underlying network 
of genes using GeneMANIA. The derived network included genes also found to be overexpressed in 
patients with high MELK expression (marked in yellow) as well as genes which are among the top 50 
overexpressed genes of the PR subgroup of myeloma (marked in blue). F) Overall survival of newly-
diagnosed MM patients treated within the total therapy 2 or 3 protocols based on MELK, PLK1, EZH2, 
FOXM1 and DEPDC1 expression. Patients were grouped according to overexpression of 0, 1-2 and ≥3 



























OTSSP167, bendamustine, carfilzomib, bortezomib, lenalidomide, and pomalidomide were obtained 
from SelleckChem, dissolved in DMSO and stored at -20°C. Dexamethasone and melphalan were 
obtained from Sigma-Aldrich, dissolved in DMSO and stored at -20°C.  
Cells and culture conditions 
Human multiple myeloma cell lines (HMCLs) U266, KMS-12-BM, OPM-2, NCI-H929, SK-MM-1 and 
RPMI8226 were obtained from the German Collection of Microorganisms and Cell Cultures. MM.1S 
cells were kindly provided by Dr. Steven Rosen (Northwestern University, Chicago, IL). MM.1R and 
HEK293T cells were obtained from the American Type Culture Collection. Human bone marrow 
mesenchymal stromal cells immortalized by enforced expression of telomerase were kindly provided 
by Dr. Dario Campana (St. Jude Children's Research Hospital, Memphis, TN).  
Primary MM and peripheral blood mononuclear cells (PBMCs) were purified from MM patients 
undergoing routine BM aspiration at the Department of Medicine I (Wihelminenspital, Vienna). 
Written informed consent for the use of material for scientific studies was obtained from these 
patients according to institutional guidelines. Mononuclear cells were isolated by Ficoll-Hypaque 
density sedimentation and MM cells were purified using the EasySepTM Human CD138 Positive 
Selection Kit (Stem Cell Technologies). 
Lentiviral transduction 
MELK specific shRNA cloned into the pLKO.1 vector was obtained from Sigma-Aldrich 
(#TRCN0000196420). Lentiviral particles were produced using a lipofectamine 3000 (ThermoFisher 
Scientific) based protocol. Briefly, HEK293T cells were transfected with pLKO.1 vector in conjunction 
with pMD2.G envelope plasmid (kind gift from Didier Trono, Addgene plasmid #12259) and 
pCMVR8.74 packaging plasmid (kind gift from Didier Trono, Addgene plasmid #22036). Viral 
supernatant was collected 24h and 52h post transfection. For lentiviral transduction, HMCLs (5x 105) 
were spin transfected (1h, 800g) with 1 ml of viral supernatant and incubated overnight. Transduced 
MM cells were selected with puromycin (1µg/ml) and used for further experiments. Cells transduced 
with pLKO.1 carrying scrambled shRNA (kind gift from David Sabatini, Addgene plasmid #1864) 
served as control. 
 
Flow cytometry 
Induction of apoptosis was analysed by AnnexinV/7-AAD staining (BD Biosciences) 72h post 
treatment. Cell cycle analysis was performed 48h post treatment using FxCycle™ PI/RNase Staining 
solution (ThermoFisher Scientific). Depolarization of the mitochondrial membrane potential was 
analysed 24h post treatment using JC-1 assay (ThermoFisher Scientific). Cells positive for cleaved-
PARP were determined 20h post treatment using anti-cleavedPARP antibody (BD Biosciences) and 
the Cytofix/Cytoperm staining procedure (BD Biosciences). All assays were performed according to 
the manufacturer’s instructions. Analyses were performed on a FACScan and FACS Canto II (BD 
Biosciences). 
Quantitative RT-PCR 
Total RNA was isolated using RNeasy kit (Qiagen), and cDNA synthesis was performed with M-MuLV 
reverse transcriptase (New England Biolabs). AURKA, IRF4, MYC, CCND1, CCNB1, PLK1, EZH2, FOXM1, 
DEPDC1 and MCL-1 expression levels were analysed by quantitative PCR (qPCR) using TaqMan 
Universal PCR Master Mix and pre-designed TaqMan gene expression assays (ThermoFisher 
Scientific). RPLPO served as endogenous control. Reactions were carried out in 25 μl volumes and run 
on the ABI Prism7300 platform (ThermoFisher Scientific). 
Western Blot 
Protein lysates were obtained using complete lysis solution (Sigma-Aldrich), quantified with 
Coomassie Protein-Assay Reagent (ThermoFisher Scientific) and analysed by immunoblotting using 
anti-MELK, anti-PLK1, anti-EZH2, anti-GAPDH, anti-βactin, anti-MCL1, anti-IRF4, anti-cleaved 
caspase3 (all from CellSignalingTechnology), anti-DEPDC1 (Abcam) and anti-FOXM1 antibodies 
(SantaCruz Biotechnology). After incubation with HRP-conjugated secondary antibodies immunoblots 
were analysed using ECL Prime Western Blotting Detection Reagent (GE Healthcare LifeSciences) and 
the FusionSolo 6S imaging-system (Vilber-Lamour). 
In vivo study 
For studies in the murine 5TGM.1 myeloma model, 5x105 5TGM.1GFP+ cells were injected i.v. in 
C57/KaLwRij mice (Envigo). When mice presented signs of myeloma, such as paraplegia, all mice 
were sacrificed, blood was collected through an intracardiac puncture and spleen, femur and tibia 
were isolated. Bone marrow infiltration of MM cells was determined by flow cytometry. Blood cell 
counts were performed using Cell-Dyn 3700 (Abbott). Serum paraprotein levels were determined 
with the mouse IgG2b ELISA read-set-go kit (eBioscience) according to the supplier’s protocol. A 
paraplegia score was determined throughout the study as required by our ethics protocol. This score 
takes the activity, posture and occurrence of hind-limb paraplegia into account.  
Analysis of GEP data 
The following datasets from the Gene Expression Omnibus (GEO) were selected for this study: 
GSE24080 (551 newly-diagnosed MM patients), GSE6477 (15 healthy controls, 22 MGUS patients, 24 
SMM patients, 73 newly-diagnosed and 28 relapsed MM patients), GSE31161 (346 TT2-baseline and 
127 TT2-relapse samples, 433 TT3-baseline and 29 TT3-relapse samples), GSE2113 (7 MGUS patients, 
39 MM patients and 6 patients suffering from plasma cell leukemia (PCL)), GSE13591 (5 healthy 
controls, 11 MGUS, 133 MM, and 9 PCL patients) and GSE9782 (264 relapsed and/or refractory MM 
patients treated with bortezomib or dexamethasone). Raw CEL files were downloaded from GEO and 
analyses were performed on gcrma-normalized samples in R using the ‘affy’ package from 
Bioconductor. For GSE9782, mas5 expression sets were retrieved for analysis using the GEOquery 
package, since raw CEL files are not provided for this study.  
Categorization of newly-diagnosed patients into distinct GEP-defined subgroups (GSE24080) was 
performed by Zhan et al. (Blood, 2006). This study identified seven distinct GEP-subgroups of 
myeloma. Four of these subgroups represent major genetic lesions in MM that arise from 
translocations on the immunoglobulin heavy chain locus. These groups are identified by the spiked 
expression of the translocated genes on the partner chromosome (CCND1, CCND3, c-MAF or MAFB, 
and MMSET). In contrast, hyperdiploidy had a distinct gene expression profile (associated with 
hyperdiploid karyotypes). The low bone disease group distinguished itself by low level expression of 
Wnt signalling inhibitory genes (DKK1 and FRZB), interferon-induced genes and high expression of 
endothelin 1 (EDN1). Clinically, these patients were characterized by a lower number of MRI-defined 
focal lesions. The proliferation (PR) subgroup is defined by overexpression of various cell 
cycle/proliferation associated genes and cancer testis antigens as well as higher GEP-defined 
proliferation index. Finally, the authors defined a myeloid signature which is characterized by 
contamination of MM cell samples with myeloid and/or normal plasma cells but also superior clinical 
performance. 
Metacore enrichment analysis 
Pathway enrichment analysis was performed using MetaCoreTM (version 6.28) analytical software. 
Genes differentially expressed (min 2-fold up- or downregulation in samples with high MELK 
expression versus samples with low MELK expression, adjusted P-value <0.05) were imported into 
MetaCore. Enrichment analyses (hypergeometric test) were run on 3 ontologies: Pathway maps, GO 
processes, and process networks. These ontologies were ordered according to their P-value, based 
on hypergeometric distribution.  
Supplementary Table 1.  Genes differentially expressed in patients with high compared to 
low MELK expression. Genes listed in the supplemental Excel file 
(Suppl Table 1) are either > 2 fold (FC, fold change) under- or 
overexpressed in patients with high compared to low MELK 
expressing myeloma cells. Listed genes (symbol) with significant 
(adjusted P-value <0.05) deregulation compared to patients with low 
MELK expression are included in the list together with the 
corresponding microarray probeset IDs (Probe ID). AveExpr indicates 
gcrma-normalized average expression values of the corresponding 
genes in patients with high MELK expression. Analysis was performed 
using the GSE24080 expression dataset. 
 
  
Supplementary Table 2.  Gene set enrichment analysis of genes upregulated in patients with 
high MELK expression. This analysis confirmed the strong association 
between genes enriched in MELKhigh patients and proliferation. As 
indicated by the graph at the bottom of the page 73% of top 10 GO 





















FDR, False discovery rate; Nb, number. 
 
  








Mitotic cell cycle 8.45E-79 2.74E-75 103 
Cell cycle 4.70E-74 7.62E-71 118 
Cell cycle process 3.08E-72 3.33E-69 109 
Mitotic cell cycle process 1.62E-66 1.31E-63 91 
Nuclear division 2.99E-46 1.94E-43 63 
Organelle fission 4.44E-45 2.40E-42 63 
Cell division 6.71E-44 3.10E-41 60 
Mitotic nuclear division 5.51E-41 2.23E-38 52 
Organelle organization 2.67E-34 9.60E-32 119 
Cell cycle phase transition 1.37E-33 4.45E-31 45 
    
Enrichment by process networks    
Cell cycle core 8.75E-41 7.87E-39 37 
Cell cycle mitosis 2.12E-22 9.54E-21 29 
Cell cycle S phase 3.36E-22 1.01E-20 27 
Cell cycle G2-M 2.27E-18 5.10E-17 27 
Cytoskeleton spindle microtubules 1.14E-16 2.05E-15 20 
Cell cycle G1-S 3.68E-12 5.06E-11 19 
DNA damage checkpoint 3.93E-12 5.06E-11 17 
DNA damage MMR repair 2.33E-07 2.62E-06 9 
DNA damage BER-NER repair 7.64E-07 7.64E-06 11 
DNA damage DBS repair 1.43E-06 1.29E-05 11 
    
Enrichment by pathway maps    
Cell cycle The metaphase checkpoint 9.09E-18 2.01E-15 13 






Cell cycle Start of DNA replication in 











DNA damage Role of Brca1 and Brca2 











Cell cycle (generic schema) 4.29E-08 1.35E-06 6 
Cell cycle Initiation of mitosis 1.36E-07 3.74E-06 6 












Supplementary Table 3. Patient characteristics of primary MM cell samples used for in vitro 
testing of OTSSP167. 
 
# Gender Age Status Isotype ISS FISH 
MM1 Female 75 Newly-diagnosed MM κ– light chains III amp1q21 
MM2 Female 76 Relapsed MM IgGκ II Trisomy 11, trisomy 13q14 
MM3 Female 79 Relapsed MM IgGκ II N/A 
MM4 Female 68 Primary Plasma Cell Leukaemia IgGλ III t(14;16), del13q14, del17p, 
amp1q21 
MM5 Female 37 Secondary Plasma Cell 
Leukaemia 
IgGκ III del13q14, translocation 
14q32 (unknown partner) 
MM6 Male 65 Refractory MM IgGκ N/A amp1q21 
MM7 Male 78 Relapsed MM IgGκ II normal 




















Supplementary Table 4. Synergistic activity of OTSSP167 in combination with 
immunomodulatory drugs (lenalidomide or pomalidomide) or 
dexamethasone at varying concentrations. Combination index (CI) 
values were determined with Compusyn. CI values <0.85, 0.85-1.15, 























5 10 2.62 5 0.5 1 5 0.5 0.78 
5 100 0.45 5 1.0 0.91 5 1.0 0.67 
5 250 0.7 5 2.5 0.74 5 2.5 0.7 
10 10 1.4 10 0.5 0.66 10 0.5 0.32 
10 100 0.45 10 1.0 0.62 10 1.0 0.5 
10 250 0.56 10 2.5 0.63 10 2.5 0.62 
20 10 0.86 20 0.5 0.39 20 0.5 0.22 
20 100 0.36 20 1.0 0.36 20 1.0 0.2 
20 250 0.38 20 2.5 0.36 20 2.5 0.26 




















5 10 0.62 5 0.5 1.04 5 0.5 0.52 
5 100 0.29 5 1.0 0.78 5 1.0 0.44 
5 250 0.38 5 2.5 1.21 5 2.5 0.64 
10 10 0.8 10 0.5 0.59 10 0.5 0.28 
10 100 0.32 10 1.0 0.76 10 1.0 0.28 
10 250 0.34 10 2.5 0.81 10 2.5 0.34 
20 10 0.74 20 0.5 0.5 20 0.5 0.21 
20 100 0.27 20 1.0 0.52 20 1.0 0.22 
20 250 0.26 20 2.5 0.51 20 2.5 0.23 




















5 10 0,45 5 0.5 0,36 5 0.5 0,25 
5 100 0,24 5 1.0 0,26 5 1.0 0,21 
5 250 0,29 5 2.5 0,33 5 2.5 0,21 
10 10 0,49 10 0.5 0,46 10 0.5 0,34 
10 100 0,21 10 1.0 0,36 10 1.0 0,29 
10 250 0,23 10 2.5 0,35 10 2.5 0,28 
20 10 0,34 20 0.5 0,4 20 0.5 0,39 
20 100 0,17 20 1.0 0,36 20 1.0 0,34 
20 250 0,15 20 2.5 0,36 20 2.5 0,37 
MEDIAN  0.24   0.36   0.29 
 Supplementary Figure 1 │ Overall survival of patients with MELKpresent and MELKabsent myeloma 
cells. Presence or absence of MELK expression in MM cells was determined using the Presence-
Absence calls with Negative Probesets (PANP) method. MELKpresent expression was associated with 






Supplementary Figure 2 │ High expression of proliferation associated genes is associated with poor 
prognosis. Newly- diagnosed patients treated within the total therapy 2 and 3 protocols (GSE24080) 
were grouped according to high or low expression of proliferation associated genes. High expression 




 Supplementary Figure 3 │ Bone marrow stromal cell (BMSC) and peripheral blood mononuclear 
cell (PBMC) viability post OTSSP167 treatment. Viability of bone marrow stromal cells (BMSCs) or 
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Supplementary Figure 4 │ Drug combination effects of OTSSP167 with proteasome inhibitors and 
alkylating agents. HMCLs were treated with OTSSP167 in combination with proteasome inhibitors 
(bortezomib, carfilzomib), melphalan or bendamustine for 96 h at the indicated concentrations. 
Combination index (CI) values were determined with Compusyn. CI values <0.85, 0.85-1.15, or >1.15 
indicate synergistic (*), additive (+) or antagonistic (#) drug activity, respectively. §, not evaluable due 
to viability >100% with one or both drugs of the combination. 
